No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
DWTI signs a collaborative research agreement with Nagoya Universities for the creation of schizophrenia treatment drugs.
DWTI <4576.T> announced on the 27th that it has signed a collaborative research agreement with Nagoya Universities to create innovative treatments for schizophrenia. Schizophrenia is a severe mental disorder that affects about 1% of the population, characterized by positive symptoms such as hallucinations and delusions, negative symptoms like a decrease in motivation, and cognitive dysfunction. In this collaborative research, the company's developed low molecular compounds will be utilized, and Professor Norio Ozaki, a specially appointed professor in the Department of Psychiatry at Nagoya University's Graduate School of Medicine, will be involved, along with AMED (Japan Agency for Medical Research and Development).
D. Western Therapeutics Institute: Extraordinary Report
A steady and resilient U.S. Stocks market is providing support.
[Emerging Markets Individual Stock Strategy] Today's Emerging Markets are expected to show a solid performance. In yesterday's US stock market on the 25th, the Dow Inc rose slightly by $4.18 (+0.01%) to $42,587.50, marking a three-day increase. The market was buoyed by buying interest following President Trump's indication of a flexible stance regarding 'reciprocal tariffs.' However, the decline in the Consumer Confidence Index raised concerns about an economic slowdown, causing a temporary dip in the market. Nevertheless, the drop in long-term interest rates provided support, allowing the market to recover into positive territory. Today's Emerging Markets are favorable for buying.
D. Western Therapeutics Institute: Confirmation
D. Western Therapeutics Institute: Financial Report - 27th Term (2024/01/01 - 2024/12/31)
DWTI rebounds for the first time in five days around unchanged, with the Rhokinase inhibitor developed being administered to subjects at the licensing destination.
DWTI<4576.T> rebounded for the first time in five days around unchanged, reaching 121 yen, up 6 yen at one point. After the market close on the 18th, the company announced that it received a notification from its licensing partner Kowa (Nagoya, Aichi Prefecture) stating that the administration to subjects in the Global Phase 3 clinical trial of the eye drop "K-321" containing the active ingredient Rhokinase inhibitor "Ripastizil hydrochloride hydrate" has been completed, which was viewed as significant. This trial focuses on patients with Fuchs' endothelial corneal dystrophy.